嘉兴地区急性缺血性卒中合并心房颤动患者抗凝治疗现状分析

doi:10.3969/j.issn.1673-5765.2021.08.002

摘要/Abstract

摘要： 目的调查嘉兴地区急性缺血性卒中合并心房颤动患者的抗凝治疗现状。方法回顾性分析2016年1月-2020年12月基于CT临床数据采集系统对卒中医疗质量改进的研究登记库-Ⅱ（computer analysing system to improve stroke management quality evaluation-Ⅱ，CASE-Ⅱ）中的嘉兴地区卒中中心登记的急性缺血性卒中合并心房颤动住院患者的信息。根据患者出院是否带有抗凝药物分为出院抗凝组与出院未抗凝组，比较两组患者的基本特征，采用logistic回归分析出院抗凝药物使用的影响因素；并进一步在既往诊断心房颤动且卒中高危（CHA2DS2-VASc≥2分）患者亚群中分析抗凝药物使用的影响因素。结果共纳入患者2005例，平均年龄77±8岁，男性979例（48.8%），NIHSS中位评分5（2～13）分。无抗血栓治疗禁忌证患者1817例，出院时带抗血栓药物比例为83.9%（1525/1817），其中抗凝药物比例为41.3%（750/1817）。年龄（OR 0.964，95%CI 0.952～0.976），基线NIHSS评分（OR 0.935， 95%CI 0.920～0.951），住院时间（OR 1.045，95%CI 1.025～1.066），深静脉血栓（OR 2.797， 95%CI 1.472～5.311），住院期间是否发生任意的颅内出血（OR 0.085，95%CI 0.038～0.188）、消化道出血（OR 0.503，95%CI 0.257～0.985）、肺炎（OR 0.646，95%CI 0.488～0.856）是急性缺血性卒中合并心房颤动患者出院接受抗凝治疗与否的独立影响因素。既往诊断心房颤动且卒中高危患者接受抗凝治疗比例仅为16.0%（153/954），低龄（OR 0.957，95%CI 0.938～0.975）、低收缩压（OR 0.985， 95%CI 0.977～0.993）、卒中/TIA病史（OR 2.773，95%CI 1.954～3.936）是其接受抗凝治疗的独立保护因素。结论嘉兴地区急性缺血性卒中合并心房颤动患者的抗凝治疗率较低，低龄、低基线NIHSS评分、长住院时间、合并深静脉血栓的患者更多接受抗凝治疗，住院期间发生颅内出血、消化道出血和肺炎的患者更少接受抗凝治疗。

文章导读： 来自CASE-Ⅱ嘉兴地区卒中中心2016年1月-2020年12月的数据显示，嘉兴地区急性缺血性卒中合并心房颤
动患者的抗凝治疗率（41.3%）较低，低龄、低基线NIHSS评分、长住院时间、合并深静脉血栓有利于抗凝药物的使
用，而住院期间发生颅内出血、消化道出血和肺炎不利于抗凝药物的使用。

关键词: 急性缺血性卒中; 心房颤动; 抗凝治疗; 嘉兴

Abstract: Objective To investigate the current status of anticoagulant therapy in acute ischemic stroke (AIS) patients with atrial fibrillation (AF) in Jiaxing. Methods This retrospective analysis enrolled the AIS inpatients with AF in Jiaxing between January 2016 and December 2020 from the Computer Analysing System to Improve Stroke Management Quality Evaluation-Ⅱ (CASE-Ⅱ) stroke registration database. The patients were divided into anticoagulation group and non-anticoagulation group according to whether they received anticoagulants or not at discharge. The baseline characteristics of the two groups were compared, and multivariate logistic regression analysis was used to determine the influencing

factors for using anticoagulants at discharge. The influencing factors for using anticoagulants in the

patients with AF and high stroke risk (CHA2DS2-VASc≥2 points) were analyzed. Results A total of 2005 patients were included, with a mean age of 77±8 years old and 979 (48.8%) males. The median baseline NIHSS was 5 (2-13). 83.9% (1525/1817) of them received antithrombotic drugs at discharge, of which 41.3% (750/1817) received anticoagulants. Age (OR 0.964, 95%CI 0.952-0.976), baseline NIHSS score (OR 0.935, 95%CI 0.920-0.951), the length of hospital stay (OR 1.045, 95%CI 1.025-1.066), deep vein thrombosis (OR 2.797, 95%CI 1.472- 5.311), any intracranial hemorrhage during hospitalization (OR 0.085, 95%CI 0.038-0.188), gastrointestinal hemorrhage (OR 0.503, 95%CI 0.257-0.985) and pneumonia (OR 0.646, 95%CI 0.488-0.856) were independent influencing factors for receiving anticoagulation at discharge. Only 16.0% (153/954) of the AF patients with high stroke risk received anticoagulation, and younger (OR 0.957, 95%CI 0.938-0.975), lower systolic blood pressure (OR 0.985, 95%CI 0.977-0.993) and history of stroke/TIA (OR 2.773, 95%CI 1.954-3.936) were independent protective factors for receiving anticoagulation in the AF patients with high stroke risk. Conclusions The anticoagulation rate of AIS patients with AF in Jiaxing was low. Yonger, lower baseline NIHSS score, longer length of hospital stay, and deep vein thrombosis were positive influencing factors for anticoagulation, and any intracranial hemorrhage during hospitalization, gastrointestinal hemorrhage and pneumonia were negative influencing factors for anticoagulation.

Key words: Acute ischemic stroke; Atrial fibrillation; Anticoagulant therapy; Jiaxing

张丹凤, 邱刚, 喻国燊, 奚振华, 潘文良, 马小董. 嘉兴地区急性缺血性卒中合并心房颤动患者抗凝治疗现状分析[J]. 中国卒中杂志, 2021, 16(08): 763-769.

ZHANG Dan-Feng, QIU-Gang, YU Guo-Shen, XI Zhen-Hua, PAN Wen-Liang, MA Xiao-Dong. Current Status of Anticoagulant Therapy in Acute Ischemic Stroke Patients with Atrial Fibrillation in Jiaxing[J]. Chinese Journal of Stroke, 2021, 16(08): 763-769.

参考文献

[1] 黄从新，张澍，黄德嘉，等. 心房颤动：目前的认识和
治疗建议（2018）[J]. 中华心律失常学杂志，2018，22
（4）：279-346.
[2] 李雪琦，马力，王晨. 非瓣膜病心房颤动患者住院期
间抗凝治疗现状及影响因素[J]. 临床药物治疗杂志，
2021，19（3）：45-50.
[3] ARONIS K N，THIGPEN J L，TRIPODIS Y，et
al. Paroxysmal atrial fibrillation and the hazards
of under-treatment[J/OL]. Int J Cardiol，2016，202：
214-220[2021-02-10]. https：//doi. org/10. 1016/j.
ijcard. 2015. 09. 006.
[4] MAZUREK M，SHANTSILA E，LANE D A，et
al. Secondary versus primary stroke prevention in
atrial fibrillation：insights from the darlington atrial
fibrillation registry[J]. Stroke，2017，48（8）：2198-
2205.
[5] OGILVIE I，NEWTON N，WELNER S A，et al.
Underuse of oral anticoagulants in atrial fibrillation：
a systematic review[J]. Am J Med，2010，123（7）：
638-645.
[6] GEBREYOHANNES E A，BHAGAVATHULA A
S，TEGEGN H G. Poor outcomes associated with
antithrombotic undertreatment in patients with atrial
fibrillation attending Gondar University Hospital：a
retrospective cohort study[J/OL]. Thromb J，2018，16：
22[2021-01-10]. https：//doi.org/10.1186/s12959-018-

0177-1.

[7] 中华医学会神经病学分会，中华医学会神经病学分
会脑血管病学组. 中国急性缺血性脑卒中诊治指南
2018[J]. 中华神经科杂志，2018，51（9）：666-682.
[8] 中华医学会，中华医学会临床药学分会，中华医学会
杂志社，等. 高血压基层合理用药指南[J]. 中华全科
医师杂志，2021，20（1）：21-28.
[9] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南
（2020年版）[J]. 中华内分泌代谢杂志，2021，37（4）：
311-398.
[10] 浙江省预防医学会心脑血管病预防与控制专业委员
会，浙江省预防医学会慢性病预防与控制专业委员
会. 血脂异常基层健康管理规范[J]. 心脑血管病防治，
2021，21（2）：105-112.
[11] BECKER R C，MEADE T W，BERGER P B，et
al. The primary and secondary prevention of
coronary artery disease：American College of
Chest Physicians Evidence-Based Clinical Practice
Guidelines（8th Edition）[J/OL]. Chest，2008，133（6
Suppl）：776S-814S[2021-02-10]. https：//doi.org/10.
1378/chest.08-0685.
[12] EASTON J D，SAVER J L，ALBERS G W，et al.
Definition and evaluation of transient ischemic attack：
a scientific statement for healthcare professionals
from the American Heart Association/American
Stroke Association Stroke Council；Council on
Cardiovascular Surgery and Anesthesia；Council on
Cardiovascular Radiology and Intervention；Council
on Cardiovascular Nursing；and the Interdisciplinary
Council on Peripheral Vascular Disease. The
American Academy of Neurology affirms the
value of this statement as an educational tool for
neurologists[J]. Stroke，2009，40（6）：2276-2293.
[13] HACKE W，KASTE M，FIESCHJ C，et a1.
Intravenous thrombolysis with recombinant tissue
plasminogen activator for acute hemispheric stroke.
The European Cooperative Acute Stroke Study
（ECASS）[J]. JAMA，1995，274（13）：1017-1025.
[14] 王拥军，李子孝，谷鸿秋，等. 中国卒中报告2019（中
文版）（3）[J]. 中国卒中杂志，2020，15（12）：1251-
1263.
[15] 闫静静，秦明照. 中国老年心房颤动患者抗凝治疗现
状及分析[J]. 中国全科医学，2018，21（27）：3285-
3289.
[16] 《老年人心房颤动诊治中国专家建议》写作组，中
华医学会老年医学分会，中华老年医学杂志编辑委
员会. 老年人非瓣膜性心房颤动诊治中国专家建议
（2016）[J]. 中华老年医学杂志，2016，35（9）：915-
928.
[17] HANNAWI Y，HANNAWI B，RAO C P V，et al.
Stroke-associated pneumonia：major advances and
obstacles[J]. Cerebrovasc Dis，2013，35（5）：430-
443.
[18] LIN L J，CHENG M H，LEE C H，et al. Compliance
with antithrombotic prescribing guidelines for
patients with atrial fibrillation—a nationwide
descriptive study in Taiwan[J]. Clin Ther，2008，30
（9）：1726-1736.
[19] CHIANG C E，WANG K L，LIP G Y. Stroke
prevention in atrial fibrillation：an Asian
perspective[J]. Thromb Haemost，2014，111（5）：
789-797.
[20] SACKS D，BAXTER B，CAMPBELL B C V，et
al. Multisociety consensus quality improvement
revised consensus statement for endovascular
therapy of acute ischemic stroke：from the American
Association of Neurological Surgeons（AANS），
American Society of Neuroradiology（ASNR），
Cardiovascular and Interventional Radiology Society
of Europe（CIRSE），Canadian Interventional
Radiology Association（CIRA），Congress of
Neurological Surgeons（CNS），European Society
of Minimally Invasive Neurological Therapy
（ESMINT），European Society of Neuroradiology
（ESNR），European Stroke Organization（ESO），
Society for Cardiovascular Angiography and
Interventions（SCAI），Society of Interventional
Radiology（SIR），Society of Neurointerventional
Surgery（SNIS），and World Stroke Organization
（WSO）[J]. J Vasc Interv Radiol，2018，29（4）：441-
453.
[21] MIKKELSEN A P，HANSEN M L，OLESEN J
B，et al. Substantial differences in initiation of oral
anticoagulant therapy and clinical outcome among
non-valvular atrial fibrillation patients treated in
inpatient and outpatient settings[J]. Europace，2016，
18（4）：492-500.